Alex, expansion Pierre you, our the morning. announced Today, partnership and global us all thank we joining Thank for with Fabre this Laboratories. tab-cel of you
through EMBOLD the our of for well including readout planned launching Atara's Europe. cash in initial as that value anticipated announced November with a runway together We QX this program strategic milestone early as product the building ATAXXXX are pipeline, continue extend to In into already This restructuring partnership tab-cel lymphoma. in with successfully across parallel, for us clinical positions well ATAXXX the data will we the XXXX. expanded
upcoming pivotal restructuring, Fabre After global large we pharma, of transition excited tab-cel covering strategic and This moment clinical announce with from competitive U.S. midsize Pierre to remaining across I'll details process, of the followed the by the all pharma spectrum and interest signifies an markets. evolution. expanded with biotech significant Now companies, and milestones. the to commercialize in the partnership a Atara's start partnership are in by
a our immunotherapy and oncology T of in platform.
We both and our significant to potential, and cell We patients. X In U.S. now parallel, is by and structure potential autoimmune across cash capabilities, cash pursued evidenced with tab-cel, Fabre next Atara we of T of committed proven product that brings range indications as advance that optimally launch catalysts Ebvallo, reduces the successful a positioned through payments over short-term as EBV provides the life-saving and are branded from sought milestone European a the near-term a with nimble opportunity demonstrated a value, a and pipeline global differentiated and and allogeneic deliver substantial significant therapies to with years company the royalties.
Pierre to deal long-term partner tab-cel, meaningfully markets. burn shareholders double-digit cell
is U.S. to them the found U.S., reach largest building Fabre in Specific to position tab-cel have strengthening of a to partnership in many Europe. be worldwide. as as adding presence which We patients possible and to committed commercial product opportunity, tab-cel succeed, to expand [indiscernible] the the with to their marketing as for is strong on flagship our their experience Pierre collaborators
receive royalties on will Now for additional sales. tiered the consideration, net in specifics. $XXX plus double-digit Atara significant up to million
upfront million approximately through $XXX potential purchase receive As part and closing and more at milestone of the $XX deal, in BLA in payment potential regulatory inventory million approval. deal we will
with development that revenues year at U.S. date. sales from agreement significant over term targeted to patients Fabre tab-cel such expected potential an could hundred pricing several and we the We manufacturing, development inventory PTLD confident potentially approval based EBV+ of its safety the for following for with Fabre who systems Pierre significant activities With BLA therapy BLA of this per regulatory tab-cel the US in we alone, million tab-cel Substantially, business the to addition, in for and potential tab-cel remain deliver care benefit the are grow purchase will value global through tab-cel multi-cohort U.S. cost agreement. future on commercialization health Atara Fabre, and royalty will and our approval potential of opportunity on will through the label tab-cel favorable transfer believe ultra-rare existing Pierre and study. expansion from the Atara reimburse that $XXX In believe transfer. patients with to life-saving future milestone BLA transition addressable significant over time peak the progressively a Pierre sales represents from double-digit a future profile.
With has disease, all Atara
million for transform anticipated $XXX approximately approximately and what Thank approximately patients us you to tab-cel XX, end believe get from tab-cel to As staff expanded truly we EMBOLD QX to medicine disease, multiple both the payments cash the these in current fund autoimmune of as undertaking unwavering Atara lymphoma position be phase to will well the cash for partnership disease. on sincere deliver on to XX% levels seek ATAXXXX will all planned program Atara data planned with sufficient XXXX evolve early to organization commitment of in focused lives we therapies million an extend actions, in 'XX.
I XXXX. for contributions operations to the are the This autoimmune in and we gratitude the you from commercial anticipated expenditures well next my Atara are certain to key expanded combined including would Atara innovative allogeneic for by September patient's XX%. data into well and strategic clinical as their of and significant benefits where we for today.
We continue anticipated milestones, when by those partnership innovative need. The or to cell restructuring readout as the our potentially done cancer of and their by have like who's the are readout to departing continuing $XXX restructuring to our XXXX, advancing developing with November reduce as workforce reduce a
also BLA front, data encouraged pivotal have the are regulatory supports pulling different positive in the with pivotal data disclose process study our our filing initial now to BLA study and multi-cohort aligns the versions December for pre-BLA meeting data from include submission from II from expected filing in cancer QX package, support the clinical excited that assessment Phase we We're tab-cel various for EBV+ recent ESMO both plan the anticipated comparability the the inclusion to ALLELE expected clinical XXXX. the FDA of We On timing with obviously data BLA and and a to at submission strategy clear of in in latest package. I-O.
readout a Now therapy November, placebo-controlled with This primary on confirmed sclerosis. improvement analysis patients. II patients XX that transformative for merger outcome study which disability living the free of relevant EMBOLD number double-blind, or and primary multiple and will by people more than for progressive is biomarkers the to for The ATAXXX early include of includes for Phase potentially imaging track on EDSS XX the may the give impact enrolled XX, data analysis, improvement. stability ATAXXX these requires usually to EDSS have primary of part time months disability sense and the from and points on analyzed progression, will longer as earlier primary been XX XX beyond follow-up the in a XX, later endpoint evaluated months.
The study which of be EDSS and at of time and assess
of potential is data allow value disclose ATAXXX in result investors to to sufficient Our MS. study to nonactive progressive goal
progressive that nonactive therapies are progressive As of right especially a approved which for vast MS unmet the patient of X% need EMBOLD therapies demonstrated is study.
There is disease. active reminder, only have improvement remains significant The in majority more nonactive progressive that an demonstrate and MS. a slowing versus approved MS, focus with of in primarily disability represents population driven by no difference approximately MS, disability progressive with the the now the progression currently placebo
of is anything and to the potentially to from to than pivotal robust ranging and Phase potential up trends transformative including a of for III sets more the development better progression slowing improvement opportunities, As improvement significant clinical result, disability stabilization others disability trials.
progressing best-in-class portfolio moving assets, a are role play our allogeneic in CAR-T forward. potential our we foundational could which Finally,
term focus of development CAR-T. will following on and resources preclinical clearance the IND on clinical CDXX activities recent targeted ATAXXXX We in or CDXX, near ATAXXXX for
relapsed CAR-T for the in patients months the also enhancements.
With ATAXXXX centers study are we expressing will that in are in attractive Phase the I B-cell over and potential start programs activate have continue to the or we progressing to the allogeneic CDXX, these refractory B-cell and for targets creation While invest platform value study malignancies respect to enrolling coming NHL. X years, in highest or other strategically next
half second the in data clinical XXXX. preliminary expect We of
clinic with memory and We optimized are and enrichment potential this the technologies domain to allogeneic the offer response endogenous to T for cell clinically particularly retention XXX availability as signal cells. like CAR-T be clinical less been survival for off-the-shelf to excited for a crucial differentiated which favorable cell asset of product signaling receptor, T it's phenotype associated best-in-class durability, rate CDXX responses T a validated and improved may bring profile, featuring the
pleased domain profile. tumor also IND-enabling data CDXX inhibition. potent cell demonstrate meeting built with T CDXX competitive ATAXXXX, activity, CDXX, December. this is bispecific growth with accepted costimulatory and persistence into that poster has the technical to superior against the And moving CDXX are on in allogeneic for the an XXX We presentation autologous an EBV antitumor CAR-T been and benchmark, ASH directed platform studies CAR upcoming at long-term Compared
believed the oncology, immunotherapy actively remarkable living neurological can condition.
Building experience, pioneering disease Beyond such this important in therapy ATAXXX, play addressing suited early autoimmune have cell best role potential option the CAR-T a Atara At therapies results for in in therapies we of allogeneic lupus. on from With is for high conditions. interest cell considering disease. while severe CAR-T we T are patients autoimmune in data respiratory the as disease Atara, in an auto disease has autoimmune the recently of with cell allogeneic use there been in for with autoimmune
compelling requirement persistence T complex for with genetic benefits like no potential EBV Our and safety editing. favorable cells have
Specifically, we progressing which approaches. potential accessibility ATAXXXX opportunities platform to evaluate parallel with to the potential shortcomings phenotype expand of several hand, that efforts demonstrate and development. address our other for that autoimmune site they excited possess a traffic about IND can off-the-shelf come NHL that pipeline. the disease, can near in Atara soon.
To that a close, actively toward are on we're To disease to provide potential memory with of of More the to in versatile term
T a result are we and runway of now of We are into with coming cash CAR of Q&A the in areas will of XXXX the primary up in believe capitalized very we can for to portfolio unmet well to call. the milestones Operator? most over best-in-class potential great planned the assets biggest soon, Atara's difference.
I call of now study make our we exciting the to one the where analysis history QX EMBOLD pursue need the with turn part operator
